retatrutide molecule Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by RCSB PDB - 8YW3: Cryo-EM

With consistent use, expect appetite control, improved mood and metabolic regularity by week 4 backed by science

SHANGHAI, March 6 () - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk, Eli Lilly, and Innovent Biologics.

GLP1 can help with weight loss

Journal of Translational Medicine

KFFs annual survey of private and non-federal public employers with three or more workers, which provides a current snapshot of employer-sponsored health benefits.